NEWPORT BEACH, CA-(NewMediaWire - Jun 12, 2017) - ADVANTIS
CORPORATION (OTC PINK: ADVT) finalized an agreement to distribute The
Antidote CBD drink within the United States, and is developing the
strategy to launch the drink internationally. In May, the company
introduced the product to the marketplace through Speedweed, and is
now in the process of implementing a marketing strategy to target
stores and websites nationally to stock the fully legal CBD Relax,
Focus, and Energy beverages
In the past month, Advantis has been test marketing The Antidote
Relax, Focus, and Energy beverages with a resounding success,
according to Advantis CEO, Christopher Swartz. "We tested the
product through more traditional, non-cannabis based proprietors
and found a significant demand among those looking for natural
solutions to life's daily challenges," Swartz said. "Taking on The
Antidote, an amazing, all-natural CBD product line, is a tremendous
opportunity for Advantis to establish national wholesale and retail
distribution channels for future CBD or non-THC products that we
market in the future. Demand for CBD based products through
websites, health/vitamin, convenience and other stores is growing
rapidly; we will begin to develop relationships and avenues to
expand our reach quickly with this aggressive marketing plan."
Swartz says the national launch of The Antidote line of drinks will
inform the evolving strategy to launch it internationally. "As we
absorb the data from our national sales, we are actively developing
the strategy and relationships necessary to successfully take The
Antidote global," Swartz related.
Swartz has been in the pain management space for several years,
and is a big proponent of CBD based solutions as an alternative to
opioid based ones. "I've worked to expand the viability, visibility
and reach of reliable CBD products for a long time," Swartz
explained. "The Antidote is a thoroughly tested, pure, and unique
formula that obtains the highest quality CBD material from fully
licensed industrial hemp farms that comply with the 2014 Farm Bill
Act and FDA Tariff Codes. I can't tell you how excited I am to have
the opportunity to market these tasty drinks that offer an
all-natural way to help with focus, energy and relaxation."
Recent studies have shown that CBD, the non-psychoactive
component of cannabis, is effective in reducing symptoms related to
pain, anxiety, nausea, inflammation, muscle spasm, and depression.
Several other effective uses of CBD are actively being studied by
several organizations and universities. "One of the great things
about the Antidote is that it tastes great, and our marketing
efforts will be helped by the fact that several mixed martial arts
fighters use and endorse The Antidote," Swartz concluded.to learn
more: visit www.theantidotecbd.com. and WWW.ADVANTISCORP.COM also the links below
for more info to come.
Swartz has been promising that an interview would be forthcoming
that would allow him to detail the current and prospects for
Advantis. "I sincerely apologize for the delay," Swartz said. "We
should have held off on the announcement until the date was firmly
set - it was tentative at the time of the announcement. I take full
responsibility for that." Swartz added that he will provide the
date of the interview as soon as it is confirmed.
Links to Advantis websites can be found at advantiscorp.com,
rosin6.com, elixicure.com, and
amstercan.com
Social Media Instagram Facebook
About Advantis Corporation
Advantis Corporation (ADVT) focuses on the development of
innovative products that supply the medical, research, and
pharmaceutical industries. The company additionally establishes
domestic and international partnerships with businesses that
develop and sell proprietary pain management, and consumer products
and services.
Forward Looking Statements: This news release contains
forward-looking statements made by ADVANTIS CORPORATION. All such
statements included in this press release, other than statements of
historical fact, are forward-looking statements. Although
management believes that the expectations reflected in such
forward-looking statements are reasonable, it can give no assurance
that such expectations will prove to have been correct. Actual
results may differ materially from those indicated by these
statements. The following risk factors, among others, could cause
actual results to differ materially from those described in any
forward- looking statements. These risks and uncertainties include,
but are not limited to, economic conditions, changes in the law or
regulations, demand for products of the Company, the effects of
competition and other factors that could cause actual results to
differ materially from those projected or represented in the
forward looking statements. Forward- looking statements are
typically identified by the words: believe, expect, anticipate,
intend, estimate, and similar expressions or which by their nature
refer to future events. The Company is not entitled to rely on the
safe harbor provisions of Section 27A of the Securities Act of 1933
and Section 21E of the Securities Exchange Act of 1934 because it
is not registered under either Act.
